Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovid Therapeutics Inc.

www.ovidrx.com

Latest From Ovid Therapeutics Inc.

BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science

A former senior leader in Johnson & Johnson’s medical devices business will take over the reins of the Biotechnology Innovation Organization from Jim Greenwood in June. McMurry-Heath – who also spent four years at the US FDA's device center as associate director of science – brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.

Policy Leadership

BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science

Former senior leader in J&J’s medical devices business will take over the reins from Jim Greenwood in June; an immunologist by training, McMurry-Heath brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.

Policy Leadership

BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science

Former senior leader in J&J’s medical devices business will take over the reins from Jim Greenwood in June; an immunologist by training, McMurry-Heath brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.

Policy Leadership

What Does 2020 Hold For Biopharma?

Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ovid Therapeutics Inc.
  • Senior Management
  • Jeremy Levin, CEO
    Timothy Daly, Treasurer, SVP, Fin. & Corp. Controller
    Amit Rakhit, MD, Head, R&D & CMO
    Dirk Haasner, PhD, SVP, Global Reg. Affairs
    Jason Tardio, Chief Commercial Officer
  • Contact Info
  • Ovid Therapeutics Inc.
    Phone: (646) 661-7661
    1460 Broadway
    New York, NY 10036
    USA
UsernamePublicRestriction

Register